This trial is designed to evaluate the effects of oral antifungal treatment with posaconazole
on active Crohn's disease (CD) activity and the burden of Malassezia spp. in CD patients with
the CARD9 S12N risk allele. Further, this project will investigate the hypothesis that the
microbial changes induced by antifungal treatment are associated with dampened downstream
immune responses in those with a genetic predisposition to developing strong immune responses
to Malassezia.